Skip to main content
ICCC logo

ImmuCell Corporation

ICCCNASDAQHealthcareBiotechnology

$10.56Today:- (-)1Y +68.96%

As of Oct 15, 2026 close

Market cap
$97.04M
P/E (TTM)
123.24
Forward P/E
243.60
Dividend yield
-
52-week range
$4.52$12.10
Volume (live)
-
Avg. volume (3M)
13.19K

ImmuCell (ICCC) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), ImmuCell had return on equity of -3.8% (up from -8.2%), debt-to-equity of 0.49 (down from 0.55), a current ratio of 4.26 (up from 3.41) and return on assets of 3.5% (up from -2.3%). A current ratio of 4.26 means current assets exceed current liabilities.

ImmuCell Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio2.011.732.262.543.222.80
P/B Ratio2.061.671.581.551.901.52
Price/Tangible Book2.061.681.591.561.911.53
Price/FCF45.42-----
Price/OCF22.48128.23--64.9132.62
Enterprise Value Ratios
EV/Revenue2.362.173.102.753.223.13
EV/EBITDA12.6255.03-65.7822.7849.62
EV/EBIT26.68---240.62-
EV/FCF53.35-----
Profitability & Returns
Return on Equity (ROE)-3.81%-8.21%-20.86%-7.92%-0.26%-3.57%
Return on Assets (ROA)3.49%-2.31%-7.36%-2.39%0.38%-2.18%
Return on Invested Capital (ROIC)6.51%-4.12%-13.43%-4.90%0.81%-4.62%
Return on Capital Employed (ROCE)6.40%-4.00%-13.20%-4.10%0.60%-3.60%
Leverage & Solvency Ratios
Debt/Equity0.490.550.670.410.320.38
Debt/EBITDA2.339.80-12.963.579.69
Debt/FCF10.77-----
Liquidity Ratios
Current Ratio4.263.412.734.556.425.50
Quick Ratio1.821.720.762.475.094.44
Efficiency Ratios
Asset Turnover0.630.600.390.420.450.39
Inventory Turnover1.982.491.892.264.093.68
Yield & Distribution Ratios
Earnings Yield-1.87%-4.70%-14.64%-5.28%-0.13%-2.38%
FCF Yield2.20%-0.23%-16.64%-11.68%-2.67%-6.42%
Buyback Yield-10.52%-5.41%-0.03%-2.01%-5.25%-5.78%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About ImmuCell Financial Ratios

What is ImmuCell's return on equity?

ImmuCell's return on equity (ROE) was -3.8% for fiscal 2025 (period ended Dec 31, 2025). It was -8.2% a year earlier.

What is ImmuCell's debt-to-equity ratio?

ImmuCell's debt-to-equity ratio was 0.49 for fiscal 2025 (period ended Dec 31, 2025). It was 0.55 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition